Abstract: Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).

Abstract: Cancer eradicating engineered bacteriophage are described that can display a high copy number of a targeting polypeptide that can bind a surface antigen of a cancer cell. The bacteriophage can also display a high copy number of a cancer therapy, one or more of a drug, a toxin, an inhibitor, a radionuclide, etc. The targeting polypeptides and the cancer therapies can be directly or indirectly fused to coat proteins of the phage. The engineered phage can exhibit high avidity for cancer cells and can deliver a large dose of a cancer therapy per particle to the cell.

Abstract: Sized-based detection techniques for detection of bio-nanoparticles are described. Detection nanoparticles and methods of forming the detection nanoparticles that can be utilized in the techniques are described. Detection nanoparticles can include modified bacteriophage that express a linking agent for a specific binding agent. Detection nanoparticles can bind a functional bio-nanoparticle with high specificity through specific binding of one or more entities unique to the functional bio-nanoparticle of interest. A detection nanoparticle can target an entity of a bio-nanoparticle that is relevant to its function, and as such, the methods can provide improvements in detection of complete and functional bio-nanoparticles. Size-based detection regimes can include particle displacement measurement techniques based upon Brownian motion.

Abstract: The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW:70KDa) with concentration of 10-15% and PLGA (MW:50KDa,50:50) with concentration of 10-18%.

Abstract: Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides that include specific binding agents for proteinaceous targets at a surface of the capsid head. Therapeutic compositions, e.g., antiviral compositions, and methods of forming are described. A therapeutic composition can include an engineered bacteriophage that includes a polypeptide binds a pathogen or binds a cellular receptor of a pathogen at a surface of the bacteriophage. The engineered bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).

Abstract: Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).

Abstract: The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.

Abstract: Disclosed are anti-HAAH antibodies and derivatives thereof conjugated to cytotoxic, cytostatic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods for the treatment of HAAH-expressing cancers, comprising administering to a subject the disclosed pharmaceutical compositions.

Abstract: The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW: 70 KDa) with concentration of 10-15% and PLGA (MW: 50 KDa, 50:50) with concentration of 10-18%.

Abstract: Disclosed herein are methods for treating cancer by administering to a subject a composition comprising a bacteriophage expressing a fragment of human aspartate ?-hydroxylase (ASPH) and an immune checkpoint protein inhibitor.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]. beta.-hydroxylase (HAAH). The present invention contemplates bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Abstract: Disclosed herein are methods and compositions for manufacturing nanoparticle bacteriophage-based vaccines that are useful for anti-cancer treatments. Also disclosed herein are methods of using bacteriophage-based vaccines expressing aspartyl (asparaginyl) ?-hydroxylase for treating cancer.

Abstract: The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: Provided herein are anti-ASPH chimeric antigen receptors (CARs), genetically modified immune effector cells, and use of these compositions to effectively treat ASPH expressing cancers.

Abstract: The present disclosure relates to methods of using biomarkers as early disease and patient outcome predictors. More particularly, the present disclosure encompasses methods of predicting cancer metastasis by detecting and/or quantifying aspartyl (asparaginyl) beta hydroxylase (HAAH) and matrix metalloproteinase 9 (MMP9) in a biological sample.

Abstract: The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.

Abstract: The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

Abstract: The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.